A Genome-Scale RNA-Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington's Disease

PLoS Genetics

Volumn 8, Issue 11, 2012, Pages

  Miller, John P ^a   Yates, Bridget E ^a   Al Ramahi, Ismael ^b   Berman, Ari E ^a   Sanhueza, Mario ^b   Kim, Eugene ^b   de Haro, Maria ^b   DeGiacomo, Francesco ^a   Torcassi, Cameron ^a   Holcomb, Jennifer ^a   Gafni, Juliette ^a   Mooney, Sean D ^a   Botas, Juan ^b   Ellerby, Lisa M ^a   Hughes, Robert E ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYLTRANSFERASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HUNTINGTIN; PEPTIDASE; PEPTIDYLPROLYL ISOMERASE PIN1; POLO LIKE KINASE 1; PROTEIN RRAS; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CELL ASSAY; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROSOPHILA; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; FEMALE; GENE SILENCING; GENETIC ANALYSIS; GENETIC SCREENING; GENOME; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MUTANT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUPPRESSOR GENE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; FARNESYLTRANSTRANSFERASE; GENOME, HUMAN; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; METABOLIC NETWORKS AND PATHWAYS; MICE; MITOCHONDRIA; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PYRIMIDINES; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIAZOLES;

MAMMALIA;

EID: 84870686106     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003042     Document Type: Article

References (65)

1. The Huntington's Disease Collaborative Research Group, Cell 72, 971 (Mar 26, 1993).
2. de la Monte SM, Vonsattel JP, Richardson EP Jr, (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516-525.
3. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498.
4. Cha CI, Chung YH, Shin CM, Shin DH, Kim YS, et al. (2000) Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res 853: 156-161.
5. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4: 349-362.
6. Bence NF, Sampat RM, Kopito RR, (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
7. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921-926.
8. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, et al. (2008) Cancer proliferation gene discovery through functional genomics. Science 319: 620-624.
9. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, et al. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799-2809.
10. Al-Ramahi I, Perez AM, Lim J, Zhang M, Sorensen R, et al. (2007) dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet 3: e234 doi:10.1371/journal.pgen.0030234.
11. Bauer S, Grossmann S, Vingron M, Robinson PN, (2008) Ontologizer 2.0-a multifunctional tool for GO term enrichment analysis and data exploration. Bioinformatics 24: 1650-1651.
12. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, et al. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 22: 7862-7872.
13. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211-20220.
14. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, et al. (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13: 442-449.
15. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, et al. (1988) NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981-983.
16. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R, (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17: 455-461.
17. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, et al. (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23: 190-197.
18. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58: 515-532.
19. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, et al. (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96: 1121-1129.
20. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, et al. (2004) Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 24: 7999-8008.
21. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, et al. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187: 1083-1099.
22. Khoshnan A, Ko J, Tescu S, Brundin P, Patterson PH, (2009) IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin. PLoS ONE 4: e5768 doi:10.1371/journal.pone.0005768.
23. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205: 1869-1877.
24. Cha JH, (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23: 387-392.
25. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97: 6763-6768.
26. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47: 29-41.
27. Li SH, Cheng AL, Zhou H, Lam S, Rao M, et al. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22: 1277-1287.
28. Zhai W, Jeong H, Cui L, Krainc D, Tjian R, (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123: 1241-1253.
29. Lowe DG, Capon DJ, Delwart E, Sakaguchi AY, Naylor SL, et al. (1987) Structure of the human and murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell 48: 137-146.
30. Zhang Z, Vuori K, Wang H, Reed JC, Ruoslahti E, (1996) Integrin activation by R-ras. Cell 85: 61-69.
31. Wang HG, Millan JA, Cox AD, Der CJ, Rapp UR, et al. (1995) R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol 129: 1103-1114.
32. Ivins JK, Yurchenco PD, Lander AD, (2000) Regulation of neurite outgrowth by integrin activation. J Neurosci 20: 6551-6560.
33. Oinuma I, Ishikawa Y, Katoh H, Negishi M, (2004) The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 305: 862-865.
34. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, et al. (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J 18: 2137-2148.
35. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, et al. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17: 215-224.
36. Eckerdt F, Yuan J, Saxena K, Martin B, Kappel S, et al. (2005) Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem 280: 36575-36583.
37. Xu Z, Williams BR, (2000) The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol 20: 5285-5299.
38. Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, et al. (2001) Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet 10: 1531-1538.
39. Uehara N, Matsuoka Y, Tsubura A, (2008) Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6: 186-193.
40. Kong PJ, Kil MO, Lee H, Kim SS, Johnson GV, et al. (2009) Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurol Res 31: 77-83.
41. Zang M, Hayne C, Luo Z, (2002) Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J Biol Chem 277: 4395-4405.
42. Spaargaren M, Martin GA, McCormick F, Fernandez-Sarabia MJ, Bischoff JR, (1994) The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. Biochem J 300 (Pt 2):: 303-307.
43. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, et al. (2001) MAP kinases. Chem Rev 101: 2449-2476.
44. Wang HG, Rapp UR, Reed JC, (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629-638.
45. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15: 273-285.
46. Mei M, Su B, Harrison K, Chao M, Siedlak SL, et al. (2006) Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem 99: 1377-1388.
47. Echeverria V, Burgess S, Gamble-George J, Arendash GW, Citron BA, (2008) Raf inhibition protects cortical cells against beta-amyloid toxicity. Neurosci Lett 444: 92-96.
48. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, et al. (2001) MEK kinase activity is not necessary for Raf-1 function. Embo J 20: 1940-1951.
49. Chen J, Fujii K, Zhang L, Roberts T, Fu H, (2001) Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A 98: 7783-7788.
50. O'Neill E, Rushworth L, Baccarini M, Kolch W, (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306: 2267-2270.
51. Piazzolla D, Meissl K, Kucerova L, Rubiolo C, Baccarini M, (2005) Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J Cell Biol 171: 1013-1022.
52. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
53. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF, (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465: 11-26.
54. Herrmann C, Martin GA, Wittinghofer A, (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 270: 2901-2905.
55. Taylor SJ, Shalloway D, (1996) Cell cycle-dependent activation of Ras. Curr Biol 6: 1621-1627.
56. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
57. Subramaniam S, Sixt KM, Barrow R, Snyder SH, (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324: 1327-1330.
58. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, et al. (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A 106: 4635-4640.
59. Fong LG, Frost D, Meta M, Qiao X, Yang SH, et al. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311: 1621-1623.
60. Chin PC, Liu L, Morrison BE, Siddiq A, Ratan RR, et al. (2004) The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem 90: 595-608.
61. Uesugi K, Oinuma I, Katoh H, Negishi M, (2009) Different requirement for Rnd GTPases of R-Ras GAP activity of Plexin-C1 and Plexin-D1. J Biol Chem 284: 6743-6751.
62. Conklin MW, Ada-Nguema A, Parsons M, Riching KM, Keely PJ, R-Ras regulates beta1-integrin trafficking via effects on membrane ruffling and endocytosis. BMC Cell Biol 11: 14.
63. Li X, Valencia A, Sapp E, Masso N, Alexander J, et al. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci 30: 4552-4561.
64. Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, et al. (2006) Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 21: 381-391.
65. Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, et al. (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 309: 375-386.